Physician profile
Leonel Camejo
NPI 1326008947
$3,510.73
in general payments reported to CMS, 2019-2025
21 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $583 · 2021: $1,154 · 2022: $511 · 2023: $413 · 2024: $288 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $820.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $784.20 | 2019-2024 | Farxiga |
| Glaxosmithkline, LLC. | $524.57 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $405.90 | 2021-2025 | Ozempic |
| Lilly USA, LLC | $305.81 | 2019-2023 | Mounjaro, Emgality, Synjardy |
| Abbvie INC. | $295.42 | 2021-2024 | Vraylar, Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $168.26 | 2023-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $163.15 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.67 | 2019-2022 | |
| Pfizer INC. | $148.68 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $83.05 | 2019-2022 | |
| Abbott Laboratories | $73.58 | 2021-2024 | Freestyle Libre 3 |
| Biogen, INC. | $67.25 | 2020-2021 | |
| Nevro Corp. | $66.56 | 2022-2023 | Senza |
| Allergan, INC. | $55.18 | 2019-2020 | |
| Amarin Pharma, INC. | $47.21 | 2019-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $45.76 | 2019 | |
| Astellas Pharma US INC | $43.60 | 2021 | |
| Amgen INC. | $26.22 | 2019-2022 | |
| Forte Bio-Pharma LLC | $20.00 | 2019 | |
| Smith+Nephew, INC. | $16.47 | 2019 | |
| Eisai INC. | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonel Camejo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.